TMEM9

Summary

TMEM9 (transmembrane protein 9, HGNC:18823) is a protein-coding gene on chromosome 1q32.1, encoding Proton-transporting V-type ATPase complex assembly regulator TMEM9 (Q9P0T7). Transmembrane protein that binds to and facilitates the assembly of lysosomal proton-transporting V-type ATPase (v-ATPase), resulting in enhanced lysosomal acidification and trafficking.

Involved in intracellular pH reduction; positive regulation of canonical Wnt signaling pathway; and proton-transporting V-type ATPase complex assembly. Located in bounding membrane of organelle; intercellular bridge; and mitotic spindle.

Source: NCBI Gene 252839 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 22 total
• MANE Select transcript: NM_001288565

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18823
Approved symbol	TMEM9
Name	transmembrane protein 9
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	TMEM9A
Ensembl gene	ENSG00000116857
Ensembl biotype	protein_coding
OMIM	616877
Entrez	252839

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 11 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000367330, ENST00000367332, ENST00000367333, ENST00000367334, ENST00000414605, ENST00000435310, ENST00000455367, ENST00000472411, ENST00000485839, ENST00000495205, ENST00000497582, ENST00000904676, ENST00000904677, ENST00000904678

RefSeq mRNA: 9 — MANE Select: NM_001288565 NM_001288564, NM_001288565, NM_001288566, NM_001288567, NM_001288568, NM_001288569, NM_001288570, NM_001288571, NM_016456

CCDS: CCDS1408, CCDS73001

Canonical transcript exons

ENST00000367330 — 5 exons

Exon	Start	End
ENSE00001444236	201153858	201154474
ENSE00001927890	201134772	201135815
ENSE00003704790	201151761	201151852
ENSE00003709361	201146740	201146848
ENSE00003709991	201143820	201143951

Expression profiles

Bgee: expression breadth ubiquitous, 254 present calls, max score 97.46.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.8585 / max 169.1686, expressed in 1782 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
16609	16.9629	1776
16608	1.2815	577
16605	0.8275	556
16611	0.4890	254
16610	0.1206	49
16612	0.1015	53
16606	0.0416	13
16607	0.0338	6

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
anterior cingulate cortex	UBERON:0009835	97.46	gold quality
hypothalamus	UBERON:0001898	97.38	gold quality
right adrenal gland	UBERON:0001233	97.14	gold quality
right frontal lobe	UBERON:0002810	97.14	gold quality
right adrenal gland cortex	UBERON:0035827	97.14	gold quality
left adrenal gland	UBERON:0001234	97.12	gold quality
left adrenal gland cortex	UBERON:0035825	97.04	gold quality
nucleus accumbens	UBERON:0001882	97.03	gold quality
Brodmann (1909) area 9	UBERON:0013540	97.02	gold quality
amygdala	UBERON:0001876	97.00	gold quality
secondary oocyte	CL:0000655	96.95	gold quality
prefrontal cortex	UBERON:0000451	96.95	gold quality
middle temporal gyrus	UBERON:0002771	96.82	gold quality
oocyte	CL:0000023	96.81	gold quality
adrenal cortex	UBERON:0001235	96.70	gold quality
putamen	UBERON:0001874	96.68	gold quality
caudate nucleus	UBERON:0001873	96.64	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.60	gold quality
right ovary	UBERON:0002118	96.54	gold quality
right uterine tube	UBERON:0001302	96.43	gold quality
endocervix	UBERON:0000458	96.35	gold quality
neocortex	UBERON:0001950	96.31	gold quality
ventricular zone	UBERON:0003053	96.30	gold quality
left ovary	UBERON:0002119	96.29	gold quality
adrenal gland	UBERON:0002369	96.22	gold quality
frontal cortex	UBERON:0001870	96.10	gold quality
cerebral cortex	UBERON:0000956	95.78	gold quality
forebrain	UBERON:0001890	95.76	gold quality
islet of Langerhans	UBERON:0000006	95.73	gold quality
metanephros	UBERON:0000081	95.70	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	16.56

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting TMEM9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-141-5P	99.57	67.86	897
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-324-3P	99.26	66.31	1034
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-6815-3P	99.13	68.98	1530
HSA-MIR-4434	99.10	67.01	1984
HSA-MIR-5703	99.10	67.09	2053
HSA-MIR-5001-5P	99.05	66.76	1972

Literature-anchored findings (GeneRIF, showing 11)

• phylogenetically conserved, widely expressed transmembrane protein with a potential, but unknown function in intracellular transport that localizes to lysosomes and late endosomes (PMID:12359240)
• TMEM9B is a key component of inflammatory signaling pathways and suggest that endosomal or lysosomal compartments regulate these pathways (PMID:18541524)
• TMEM9 knockdown by RNA interference resulted in G1 arrest. (PMID:27220462)
• TMEM9 plays a significant role in TNF-alpha-enhanced cytokines (IL-6 and IL-1beta) secretion in LX-2 cells and that the canonical Wnt/beta-catenin signaling pathway is involved in the induction of these cytokine expressions. (PMID:30119033)
• Data show that TMEM9 binds to and facilitates assembly of vacuolar-ATPase (v-ATPase), a vacuolar proton pump, resulting in enhanced vesicular acidification and trafficking. (PMID:30374053)
• TMEM9-activated v-ATPase downregulates APC via lysosomal degradation, which hyperactivates WNT/beta-Catenin signaling. (PMID:32380568)
• TMEM9-v-ATPase Activates Wnt/beta-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis. (PMID:32380568)
• Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis. (PMID:36336962)
• Tumor-Promoting Properties of TMEM9A in Breast Cancer Progression via Activating the Wnt/beta-Catenin Signaling Pathway. (PMID:36596527)
• TMEM9 promotes lung adenocarcinoma progression via activating the MEK/ERK/STAT3 pathway to induce VEGF expression. (PMID:38664392)
• TMEM9 activates Rab9-dependent alternative autophagy through interaction with Beclin1. (PMID:39078420)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tmem9	ENSDARG00000055757
mus_musculus	Tmem9	ENSMUSG00000026411
rattus_norvegicus	Tmem9	ENSRNOG00000010204
drosophila_melanogaster	CG1161	FBGN0037313
caenorhabditis_elegans		WBGENE00020026

Paralogs (1): TMEM9B (ENSG00000175348)

Protein

Protein identifiers

Proton-transporting V-type ATPase complex assembly regulator TMEM9 — Q9P0T7 (reviewed: Q9P0T7)

Alternative names: Dermal papilla-derived protein 4, Transmembrane protein 9

All UniProt accessions (6): Q9P0T7, B1ALM4, B1ALM5, B1ALM7, B1ALM8, F2Z389

UniProt curated annotations — full annotation on UniProt →

Function. Transmembrane protein that binds to and facilitates the assembly of lysosomal proton-transporting V-type ATPase (v-ATPase), resulting in enhanced lysosomal acidification and trafficking. By bringing the v-ATPase accessory protein ATP6AP2 and the v-ATPase subunit ATP6V0D1 together, allows v-ATPase complex formation and activation. TMEM9-controlled vesicular acidification induces hyperactivation of Wnt/beta-catenin signaling, involved in development, tissue homeostasis and tissue regeneration, through lysosomal degradation of adenomatous polyposis coli/APC. In the liver, involved in hepatic regeneration.

Subunit / interactions. Interacts with the v-ATPase accessory protein ATP6AP2 and with the v-ATPase complex subunit ATP6V0D1; these interactions lead to the assembly of the v-ATPase complex.

Subcellular location. Lysosome membrane. Late endosome membrane. Endosome. Multivesicular body membrane.

Tissue specificity. Highly expressed in adrenal gland, thyroid gland, testis, ovary and prostate. Moderate expression in trachea, spinal cord, stomach, colon, small intestine and spleen. Low expression in bone marrow, lymph node, thymus and peripheral blood lymphocytes. Expression is detected in hematopoietic cell lines including those of myeloid, erythroid, B- and T-cell origin.

Post-translational modifications. N-glycosylated.

Domain organisation. The transmembrane domain (TMD) is essential for the interaction with ATP6AP2.

Similarity. Belongs to the TMEM9 family.

RefSeq proteins (9): NP_001275493, NP_001275494, NP_001275495, NP_001275496, NP_001275497, NP_001275498, NP_001275499, NP_001275500, NP_057540 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008853	TMEM9/TMEM9B	Family

Pfam: PF05434

UniProt features (12 total): glycosylation site 3, sequence conflict 2, topological domain 2, modified residue 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
9DNX	ELECTRON MICROSCOPY	2.86
9DNY	ELECTRON MICROSCOPY	3.01
9DNZ	ELECTRON MICROSCOPY	3.16

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P0T7-F1	73.45	0.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 137, 144

Glycosylation sites (3): 21, 38, 47

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 134 (showing top): GOBP_ENDOSOME_ORGANIZATION, GOBP_VACUOLE_ORGANIZATION, GOCC_VACUOLAR_MEMBRANE, GOBP_VESICLE_ORGANIZATION, AAGCCAT_MIR135A_MIR135B, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_WNT_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_VACUOLAR_ACIDIFICATION, GOBP_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, GOBP_REGULATION_OF_PH, GOBP_POSITIVE_REGULATION_OF_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_MONOATOMIC_ION_HOMEOSTASIS

GO Biological Process (6): lysosomal lumen acidification (GO:0007042), protein transport (GO:0015031), regulation of protein catabolic process (GO:0042176), endosomal lumen acidification (GO:0048388), proton-transporting V-type ATPase complex assembly (GO:0070070), positive regulation of canonical Wnt signaling pathway (GO:0090263)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (10): lysosome (GO:0005764), lysosomal membrane (GO:0005765), late endosome (GO:0005770), microtubule cytoskeleton (GO:0015630), multivesicular body membrane (GO:0032585), intercellular bridge (GO:0045171), mitotic spindle (GO:0072686), endosome (GO:0005768), membrane (GO:0016020), late endosome membrane (GO:0031902)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
vacuolar acidification	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
regulation of catabolic process	1
protein catabolic process	1
regulation of protein metabolic process	1
endosome organization	1
intracellular pH reduction	1
proton-transporting two-sector ATPase complex assembly	1
positive regulation of Wnt signaling pathway	1
canonical Wnt signaling pathway	1
regulation of canonical Wnt signaling pathway	1
binding	1
lytic vacuole	1
lysosome	1
lytic vacuole membrane	1
endosome	1
cytoskeleton	1
multivesicular body	1
late endosome membrane	1
spindle	1
endomembrane system	1
cytoplasmic vesicle	1
late endosome	1
endosome membrane	1

Protein interactions and networks

STRING

682 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TMEM9	MINDY3	Q9H8M7	775
TMEM9	GHITM	Q9H3K2	737
TMEM9	TMEM45A	Q9NWC5	711
TMEM9	COPS7A	Q9UBW8	576
TMEM9	C11orf86	A6NJI1	489
TMEM9	RBM42	Q9BTD8	475
TMEM9	MRI1	Q9BV20	449
TMEM9	ARL6IP5	O75915	431
TMEM9	TMEM167A	Q8TBQ9	397
TMEM9	TM9SF2	Q99805	396
TMEM9	DTD2	Q96FN9	393
TMEM9	FBXL17	Q9UF56	377
TMEM9	TMEM161A	Q9NX61	374
TMEM9	SHISA4	Q96DD7	374
TMEM9	WFIKKN2	Q8TEU8	367

IntAct

93 interactions, top by confidence:

A	B	Type	Score
RINT1	NBAS	psi-mi:“MI:0914”(association)	0.830
HEATR3	TMEM186	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
STX6	TMEM9	psi-mi:“MI:0915”(physical association)	0.670
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
C2CD2L	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
CLDN1	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
TMEM60	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
TMEM9	PGAP2	psi-mi:“MI:0915”(physical association)	0.560
TMEM140	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
CLDN10	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
ATP6V0C	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
TSPO	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
NINJ2	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
TUSC5	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
SLC30A8	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
EMP1	TMEM9	psi-mi:“MI:0915”(physical association)	0.560
TMEM9	ESYT2	psi-mi:“MI:0914”(association)	0.530
SLC27A3	ATP5F1B	psi-mi:“MI:0914”(association)	0.530
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
LGALS3	PODXL	psi-mi:“MI:0914”(association)	0.530
CCT8L2	ACSL4	psi-mi:“MI:0914”(association)	0.530
SLC15A4	PGRMC1	psi-mi:“MI:0914”(association)	0.530
NRAS	ESYT2	psi-mi:“MI:2364”(proximity)	0.480
TMEM9	GALNT6	psi-mi:“MI:0915”(physical association)	0.370
SORT1	SH3PXD2B	psi-mi:“MI:0914”(association)	0.350
P/V/C	PEX1	psi-mi:“MI:0914”(association)	0.350

BioGRID (279): TMEM9 (Proximity Label-MS), TMEM9 (Proximity Label-MS), TMEM9 (Affinity Capture-MS), TMEM9 (Affinity Capture-MS), TMEM9 (Affinity Capture-RNA), TMEM9 (Affinity Capture-MS), TMEM9 (Affinity Capture-MS), TMEM9 (Proximity Label-MS), TMEM9 (Proximity Label-MS), TMEM9 (Affinity Capture-RNA), TMEM9 (Proximity Label-MS), TMEM9 (Affinity Capture-MS), TMEM9 (Two-hybrid), EMP1 (Two-hybrid), CLDN10 (Two-hybrid)

ESM2 similar proteins: A0A1B0GVV1, A0M8S0, A0M8T1, A0M8U1, A3KN28, A4D7R9, A9JRA0, B1AZA5, E9Q2Z6, P01134, P48030, Q00PJ0, Q07DV5, Q07DW9, Q07DX8, Q07DY8, Q07E08, Q07E45, Q09YH4, Q09YI5, Q09YJ7, Q09YK8, Q09YN2, Q108U3, Q1RLU8, Q2IBA8, Q2IBD0, Q2IBE0, Q2IBE8, Q2PG42, Q2QL86, Q2QLA6, Q2QLB7, Q2QLD7, Q2QLE8, Q2QLG2, Q3KRC4, Q3SXP7, Q5T292, Q68FW3

Diamond homologs: O73698, Q9CR23, Q9JJR8, Q9NQ34, Q9P0T7, Q9VNA4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

22 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	16
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1182 predictions. Top by Δscore:

Variant	Effect	Δscore
1:201135812:CATC:C	acceptor_gain	1.0000
1:201143814:TCTTA:T	donor_loss	1.0000
1:201143815:CTTAC:C	donor_loss	1.0000
1:201143816:TTAC:T	donor_loss	1.0000
1:201143817:TA:T	donor_loss	1.0000
1:201143818:A:AC	donor_gain	1.0000
1:201143819:C:CC	donor_gain	1.0000
1:201143819:C:CT	donor_loss	1.0000
1:201143819:CCT:C	donor_gain	1.0000
1:201143948:TGAC:T	acceptor_gain	1.0000
1:201146844:AGTTG:A	acceptor_gain	1.0000
1:201146845:GTTGC:G	acceptor_loss	1.0000
1:201146846:TTG:T	acceptor_gain	1.0000
1:201146846:TTGC:T	acceptor_loss	1.0000
1:201146847:TG:T	acceptor_gain	1.0000
1:201146848:GC:G	acceptor_loss	1.0000
1:201146849:C:CC	acceptor_gain	1.0000
1:201146849:C:T	acceptor_loss	1.0000
1:201146850:T:A	acceptor_loss	1.0000
1:201135811:GCATC:G	acceptor_gain	0.9900
1:201135812:CATCC:C	acceptor_gain	0.9900
1:201135813:ATC:A	acceptor_gain	0.9900
1:201135814:TC:T	acceptor_gain	0.9900
1:201135815:CC:C	acceptor_gain	0.9900
1:201135816:C:CA	acceptor_loss	0.9900
1:201135816:C:CC	acceptor_gain	0.9900
1:201135817:T:C	acceptor_loss	0.9900
1:201135818:G:C	acceptor_gain	0.9900
1:201135821:G:GC	acceptor_gain	0.9900
1:201143807:AAAGC:A	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000204387 (1:201138097 A>C,G), RS1000274154 (1:201159228 T>C), RS1000317074 (1:201147093 C>A), RS1000344153 (1:201147941 A>C), RS1000418202 (1:201153165 G>A), RS1000424324 (1:201153023 A>G), RS1000591259 (1:201159781 ACT>A), RS1000763948 (1:201151380 A>G), RS1000861338 (1:201172490 T>C), RS1000868453 (1:201171322 C>T), RS1000952616 (1:201164953 T>C), RS1000998227 (1:201138563 A>T), RS1001008849 (1:201157594 A>G), RS1001207594 (1:201165806 G>A), RS1001217589 (1:201152401 T>C,G)

Disease associations

OMIM: gene MIM:616877 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST005212_6	Asthma	2.000000e-06
GCST009391_1089	Metabolite levels	5.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010543	uridine diphosphate galactose measurement
EFO:0010544	uridine diphosphate glucose measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	2
GSK-J4	decreases expression	1
FR900359	decreases phosphorylation	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	increases reaction, affects binding	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Acetaminophen	affects response to substance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Cisplatin	increases expression	1
Doxorubicin	increases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Lead	affects expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Thiram	decreases expression	1
Tretinoin	decreases expression	1
Cyclosporine	decreases methylation	1
Cadmium Chloride	increases abundance, increases expression	1
Okadaic Acid	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E2VX	H9 AAVS1-TRE3G-NGN2 Flag-EEA1 TMEM9-/-	Embryonic stem cell	Female
CVCL_E2VY	H9 AAVS1-TRE3G-NGN2 Flag-EEA1 TMEM9-/-; TMEM9B-/-	Embryonic stem cell	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.